NCT01515553View on ClinicalTrials.gov

Bioequivalence of Two Liraglutide Formulations in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

22

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

April 30, 2007

Study Completion Date

April 30, 2007

Conditions

DiabetesHealthy

Interventions

DRUG

liraglutide

Two single doses of 0.72 mg liraglutide administered subcutaneously on two different dosing occasions separated by a wash-out period

Trial Locations (1)

221 85

Lund

Sponsors

Lead Sponsor

Novo Nordisk A/S

All Listed Sponsors

lead

Novo Nordisk A/S

INDUSTRY